0000950170-24-025427.txt : 20240305 0000950170-24-025427.hdr.sgml : 20240305 20240305081509 ACCESSION NUMBER: 0000950170-24-025427 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 14 CONFORMED PERIOD OF REPORT: 20240305 ITEM INFORMATION: Results of Operations and Financial Condition ITEM INFORMATION: Financial Statements and Exhibits FILED AS OF DATE: 20240305 DATE AS OF CHANGE: 20240305 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Aptevo Therapeutics Inc. CENTRAL INDEX KEY: 0001671584 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] ORGANIZATION NAME: 03 Life Sciences IRS NUMBER: 811567056 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-37746 FILM NUMBER: 24718371 BUSINESS ADDRESS: STREET 1: 2401 4TH AVE. STREET 2: SUITE 1050 CITY: SEATTLE STATE: WA ZIP: 98121 BUSINESS PHONE: 206-838-0500 MAIL ADDRESS: STREET 1: 2401 4TH AVE. STREET 2: SUITE 1050 CITY: SEATTLE STATE: WA ZIP: 98121 8-K 1 apvo-20240305.htm 8-K 8-K
0001671584false00016715842024-03-052024-03-05

 

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549

 

FORM 8-K

 

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): March 05, 2024

 

 

APTEVO THERAPEUTICS INC.

(Exact name of Registrant as Specified in Its Charter)

 

 

Delaware

001-37746

81-1567056

(State or Other Jurisdiction
of Incorporation)

(Commission File Number)

(IRS Employer
Identification No.)

 

 

 

 

 

2401 4th Avenue

Suite 1050

 

Seattle, Washington

 

98121

(Address of Principal Executive Offices)

 

(Zip Code)

 

Registrant’s Telephone Number, Including Area Code: (206) 838-0500

 

Not Applicable

(Former Name or Former Address, if Changed Since Last Report)

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:


Title of each class

 

Trading
Symbol(s)

 


Name of each exchange on which registered

Common Stock, $0.001 par value

 

APVO

 

The Nasdaq Stock Market LLC

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

 

Item 2.02 Results of Operations and Financial Condition.

On March 5, 2024, Aptevo Therapeutics Inc. (the “Company”) issued a press release announcing its financial results for the period ended December 31, 2023. A copy of the press release is attached hereto as Exhibit 99.1 and incorporated herein by reference.

The information in this report, including the exhibit hereto, is being furnished and shall not be deemed “filed” for purposes of Section 18 of the Securities Act of 1934, as amended, or otherwise subject to the liabilities of that section or Sections 11 and 12(a)(2) of the Securities Act of 1933, as amended. The information contained herein and in the accompanying exhibit shall not be incorporated by reference into any filing with the U.S. Securities and Exchange Commission (the “SEC”) made by the Company, whether made before, on or after the date hereof, regardless of any general incorporation language in such filing, except as shall be expressly set forth by specific reference in such filing.

 

Item 9.01 Financial Statements and Exhibits.

 

(d) Exhibits

 

Exhibit No.

 

Description

99.1

 

Press Release dated March 5, 2024.

104

 

Cover Page Interactive Data File (embedded within the Inline XBRL document)

 

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

 

 

Aptevo Therapeutics Inc.

 

 

 

 

Date:

March 5, 2024

By:

/s/ Marvin L. White

 

 

 

Marvin L. White
President and Chief Executive Officer

 

 EX-99.1 2 apvo-ex99_1.htm EX-99.1 EX-99.1

 

Exhibit 99.1

img237228349_0.jpg 

 

 

APTEVO THERAPEUTICS REPORTS 2023 FINANCIAL RESULTS AND

PROVIDES A BUSINESS UPDATE

 

Announces 1H24 Plan for Development of Lead Candidate APVO436 for the Treatment of Frontline Acute Myeloid Leukemia, Interim Results Expected Late 2H24

 

ALG.APV-527 Phase 1 Trial for the Treatment of Multiple Solid Tumors Continues Enrollment, Interim Results Expected 1H24

 

SEATTLE, WA – March 5, 2024 – Aptevo Therapeutics Inc. (Nasdaq: APVO), a clinical-stage biotechnology company focused on developing novel immune-oncology therapeutics based on its proprietary ADAPTIR™ and ADAPTIR-FLEX™ platform technologies, today reported financial results for the year ended December 31, 2023 and provided a business update.

 

Business Update

 

APVO436

•
APVO436, Aptevo’s CD3 x CD123 bispecific, is currently in clinical development for the treatment of acute myeloid leukemia (AML), of which there are approximately 20,000 new diagnoses and 11,000 deaths annually
•
In 2023, the Company concluded a multi-center, multi-cohort dose expansion study. Trial results showed a 91% clinical benefit rate in combination with venetoclax + azacitidine in venetoclax naïve patients, a less than 30% incidence of CRS across all trial cohorts (the majority were grades 1 &2) and meaningful duration of remission, including three patients who transitioned to transplant after receiving therapy. Transplant is the best possible outcome for AML patients
•
Upon review of this data and in consultation with the FDA, Aptevo intends to initiate an open- label Phase 1b/2 trial in 1H24 to further evaluate APVO436 in combination with the current standard of care, venetoclax + azacitidine, in frontline, venetoclax naïve AML patients
o
The first part of the trial consists of a Phase 1b dose optimization study that will explore multiple doses of APVO436 in combination with venetoclax + azacitidine and is expected to add to the existing body of clinical data supporting further development of APVO436 in AML
•
The Company plans to report interim data in late 2H24

 

 

 

 

1

 

“We are excited about our results and have compiled a significant body of data around APVO436 based on the trials we have completed to date. For example, we know it is safe, well tolerated, clinically active and shows a favorable duration of remission. For the next step in our APVO436 clinical program, we will target frontline AML patients who are venetoclax treatment naïve. Other populations that may benefit from APVO436, and therefore could be the focus of future clinical trials, include patients with relapsed/refractory AML and patients with myelodysplastic syndrome, both populations having been explored in earlier phases of APVO436 development. For the upcoming frontline trial, we know that the right combination is APVO436 + venetoclax + azacitidine and we have a targeted dose range. This upcoming Phase 1b/2 trial will allow us to further optimize and de-risk the regimen as it progresses to later stage development,” said Marvin White, President and Chief Executive Officer at Aptevo. “We look forward to reporting early clinical results later in the year.”

 

ALG.APV-527

•
ALG.APV-527 is a 5T4 x 4-1BB bispecific currently being evaluated in a multi-cohort, multi-center Phase 1 dose escalation trial initiated in 2023 for multiple solid tumor types representing large patient populations with significant unmet medical needs
•
The goal of the dose escalation trial is to evaluate safety and tolerability, and to evaluate the compound for signs of clinical activity
•
ALG.APV-527 is designed to overcome the safety issues of other 4-1BB agonists by 5T4-dependent immune activation. In cytokine release assays performed as part of IND-enabling studies, the Company found no evidence of increased cytokine release, that can lead to potentially serious side effects, in vitro using human peripheral blood mononuclear cells or whole blood
•
The Company believes ALG.APV-527 has the potential to be clinically important because 4-1BB can stimulate the immune cells (tumor-specific T cells and NK cells) involved in tumor control
•
Aptevo expects to provide an interim data readout in 1H24

 

“We are pleased with the progress of the ALG.APV-527 Phase 1 clinical program. We believe this drug has the potential to impact patients in large patient populations that are significantly underserved by available treatment options,” said Dirk Huebner, MD, Chief Medical Officer at Aptevo. “We look forward to reporting initial data in 1H24.”

 

 

2

 

2023 Summary Financial Results

 

Cash Position: Aptevo had cash and cash equivalents as of December 31, 2023, totaling $16.9 million.

Royalty Revenue: Royalty revenue for the period covered by this report reflects revenue recorded only in the first quarter of 2022 due to our Amendment to Royalty Purchase Agreement with HCR. As a result of the amendment, we ceased reporting as royalty revenue, royalties paid by Pfizer to HCR related to Pfizer’s sales of RUXIENCE® (rituximab-pvvr). The last quarter for which we reported this royalty revenue was Q1 2022. The Amendment had the effect of eliminating the requirement to report all future Pfizer non-cash royalty revenue and extinguishing the liability that we recorded upon the initial sale of the royalties to HCR. RUXIENCE is a registered trademark of Pfizer.

Research and Development Expenses: Research and development expenses decreased by $0.8 million, from $17.9 million for the year ended December 31, 2022 to $17.1 million for the year ended December 31, 2023. The decrease was primarily due to lower spending on the APVO436 trial costs as we concluded our Phase 1b expansion study. The decrease was partially offset by higher spending on the ALG.APV-527 trial costs as 2023 consisted of a full year of CRO and patient visit costs compared to start-up activities in 2022.

General and Administrative Expenses: General and administrative expenses decreased by $2.1 million, from $13.9 million for the year ended December 31, 2022 to $11.8 million for the year ended December 31, 2023. The decrease is primarily due to lower employee and consulting costs.

Other Income (Expense) Net:

Other Income (Expense) from Continuing Operations, Net consists of other income, net of $0.6 million for the year ended December 31, 2023 and other expense, net of $4.0 million for the year ended December 31, 2022. The change was primarily due to higher interest income from our money market funds and lower interest expense due to the principal paydown of our debt and full repayment of the outstanding balance in the first quarter of 2023. Additionally, we no longer record non-cash interest expense due to the amendment of our royalty purchase agreement with HCR in the second quarter of 2022, which eliminated the liability related to the sale of royalties and the related non-cash interest expense.

Gain Related to Sale of Non-Financial Asset consists of a $9.7 million gain recorded in Q1 2023 related to the sale of all of the deferred payments and a portion of the milestone payments from Medexus to XOMA.

Gain on extinguishment of liability related to sale of royalties covered by this report reflects a gain of $37.2 million recorded in 2022 due to our amended royalty Purchase agreement with HCR.

Milestone income related to sale of royalties related to Pfizer's net sales of RUXIENCE in fiscal year 2022 prior to amendment of our royalty purchase agreement in Q2 2022. We did not record such income in 2023.

Discontinued Operations: Income from discontinued operations was $1.2 million for the year ended December 31, 2023, consisting of $0.5 million in deferred payments from Medexus related to IXINITY sales and $0.2 million related to funds released from escrow from the sale of Aptevo BioTherapeutics

 

3

 

in 2020. Additionally, we received $0.6 million related to the sale of hyperimmune business to Saol (later acquired by Kamada, Ltd.) as a result of the collection of certain accounts receivable. As a result of our Purchase Agreement with XOMA (US) LLC in March 2023, we no longer receive deferred payments from Medexus. We are still entitled to receive a percentage of future milestones based on Medexus’ achievement of certain IXINITY net sales and regulatory approvals. Income from discontinued operations was $1.0 million for the year ended December 31, 2022, which related to collection of deferred payments from Medexus related to IXINITY sales.

Net Income (Loss): Aptevo had a net loss of $17.4 million or $1.42 per share for the year ended December 31, 2023, compared to a net income of $8.0 million or $1.57 per share for the corresponding period in 2022.

 

 

4

 

Aptevo Therapeutics Inc.

CONSOLIDATED BALANCE SHEETS

(in thousands, except share and per share amounts)

 

 

 

December 31, 2023

 

 

December 31, 2022

 

ASSETS

 

 

 

 

 

 

Current assets:

 

 

 

 

 

 

Cash and cash equivalents

 

$

16,904

 

 

$

22,635

 

Royalty and milestone receivable

 

 

—

 

 

 

2,500

 

Prepaid expenses

 

 

1,473

 

 

 

1,571

 

Other current assets

 

 

689

 

 

 

744

 

Total current assets

 

 

19,066

 

 

 

27,450

 

Property and equipment, net

 

 

895

 

 

 

1,462

 

Operating lease right-of-use asset

 

 

4,881

 

 

 

5,303

 

Total assets

 

$

24,842

 

 

$

34,215

 

LIABILITIES AND STOCKHOLDERS' EQUITY

 

 

 

 

 

 

Current liabilities:

 

 

 

 

 

 

Accounts payable and other accrued liabilities

 

$

3,984

 

 

$

3,499

 

Accrued compensation

 

 

2,098

 

 

 

2,105

 

Current portion of long-term debt

 

 

—

 

 

 

2,000

 

Other current liabilities

 

 

1,142

 

 

 

1,102

 

Total current liabilities

 

 

7,224

 

 

 

8,706

 

Long-term debt

 

 

—

 

 

 

1,456

 

Operating lease liability

 

 

5,397

 

 

 

6,079

 

Total liabilities

 

 

12,621

 

 

 

16,241

 

 

 

 

 

 

 

 

Stockholders' equity:

 

 

 

 

 

 

Preferred stock: $0.001 par value; 15,000,000 shares authorized, zero
   shares issued or outstanding

 

 

—

 

 

 

—

 

Common stock: $0.001 par value; 500,000,000 shares authorized;
   19,468,180 and 6,466,294 shares issued and outstanding at
   December 31, 2023 and December 31, 2022, respectively

 

 

61

 

 

 

48

 

Additional paid-in capital

 

 

235,607

 

 

 

223,962

 

Accumulated deficit

 

 

(223,447

)

 

 

(206,036

)

Total stockholders' equity

 

 

12,221

 

 

 

17,974

 

Total liabilities and stockholders' equity

 

$

24,842

 

 

$

34,215

 

 

 

 

5

 

Aptevo Therapeutics Inc.

CONSOLIDATED STATEMENTS OF OPERATIONS

(in thousands, except share and per share amounts)

 

 

 

For the Year Ended December 31,

 

 

 

2023

 

 

2022

 

Royalty revenue

$

 

—

 

 

$

3,114

 

Operating expenses:

 

 

 

 

 

 

Research and development

 

 

(17,107

)

 

 

(17,882

)

General and administrative

 

 

(11,771

)

 

 

(13,873

)

Loss from operations

 

 

(28,878

)

 

 

(28,641

)

Other income (expense):

 

 

 

 

 

 

Other income (expense) from continuing operations, net

 

 

578

 

 

 

(4,027

)

Gain related to sale of non-financial asset

 

 

9,650

 

 

 

—

 

Gain on extinguishment of liability related to
   sale of royalties

 

 

—

 

 

 

37,182

 

Milestone income related to sale of royalties

 

 

—

 

 

 

2,500

 

Net (loss) income from continuing operations

 

 

(18,650

)

 

 

7,014

 

Discontinued operations:

 

 

 

 

 

 

Income from discontinued operations

 

 

1,239

 

 

 

1,013

 

Net (loss) income

$

 

(17,411

)

 

$

8,027

 

 

 

 

 

 

 

 

Net (loss) income per share:

 

 

 

 

 

 

Basic

$

 

(1.42

)

 

$

1.57

 

Diluted

$

 

(1.42

)

 

$

1.57

 

Shares used in calculation:

 

 

 

 

 

 

Basic

 

 

12,234,661

 

 

 

5,100,310

 

Diluted

 

 

12,234,661

 

 

 

5,102,914

 

 

 

6

 

About Aptevo Therapeutics Inc.

Aptevo Therapeutics Inc. is a clinical-stage biotechnology company focused on developing novel immuno-oncology therapies for the treatment of cancer. Aptevo is seeking to improve treatment outcomes for cancer patients. For more information, please visit www.aptevotherapeutics.com.

Safe Harbor Statement

This press release includes forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. All statements, other than statements of historical fact, including, without limitation, Aptevo’s expectations about the activity, efficacy, safety, tolerability and durability of its therapeutic candidates and potential use of any such candidates, including in combination with other drugs, as therapeutics for treatment of disease, its expectations regarding the effectiveness of its ADAPTIR and ADAPTIR-FLEX platforms, statements related to the progress of Aptevo’s clinical programs, including statements related to anticipated clinical and regulatory milestones such as Phase 1b/2 trial initiation for APVO436 in frontline, venetoclax naïve AML patients, whether further study of APVO436 in a Phase 1b dose optimization trial focusing on multiple doses of APVO436 in combination with venetoclax + azacitidine on a targeted patient population will continue to show clinical benefit, whether Aptevo’s final trial results will vary from its earlier assessment, the possibility and timing of interim data readouts for ALG.APV-527, statements related to Aptevo’s cash position and balance sheet, statements related to Aptevo’s ability to generate stockholder value, whether Aptevo will continue to have momentum in its business in the future, and any other statements containing the words “may,” “continue to,” “believes,” “knows,” “expects,” “optimism,” “potential,” “designed,” “promising,” “plans,” “will” and similar expressions are intended to identify forward-looking statements. These forward-looking statements are based on Aptevo’s current intentions, beliefs, and expectations regarding future events. Aptevo cannot guarantee that any forward-looking statement will be accurate. Investors should realize that if underlying assumptions prove inaccurate or unknown risks or uncertainties materialize, actual results could differ materially from Aptevo’s expectations. Investors are, therefore, cautioned not to place undue reliance on any forward-looking statement.

There are several important factors that could cause Aptevo’s actual results to differ materially from those indicated by such forward-looking statements, including a deterioration in Aptevo’s business or prospects; further assessment of preliminary or interim data or different results from later clinical trials; adverse events and unanticipated problems, adverse developments in clinical development, including unexpected safety issues observed during a clinical trial; and changes in regulatory, social, macroeconomic and political conditions. For instance, actual results may differ materially from those indicated by such forward-looking statements as a result of various important factors, including the uncertainties inherent in the results of preliminary or interim data and preclinical studies being predictive of the results of later-stage clinical trials, initiation, enrollment and maintenance of patients, and the completion of clinical trials, the availability and timing of data from ongoing clinical trials, the trial design includes combination therapies that may make it difficult to accurately ascertain the benefits of APVO436, expectations for the timing and steps required in the regulatory review process,

 

1

 

expectations for regulatory approvals, the impact of competitive products, our ability to enter into agreements with strategic partners or raise funds on acceptable terms or at all and other matters that could affect the availability or commercial potential of Aptevo’s product candidates, business or economic disruptions due to catastrophes or other events, including natural disasters or public health crises such as the coronavirus (referred to as COVID-19), geopolitical risks, including the current war between Russia and Ukraine and the rising conflict in the Middle East, and macroeconomic conditions such as economic uncertainty, rising inflation and interest rates, continued market volatility and decreased consumer confidence. These risks are not exhaustive, Aptevo faces known and unknown risks. Additional risks and factors that may affect results are set forth in Aptevo’s filings with the Securities and Exchange Commission, including its Annual Report on Form 10-K for the fiscal year ended December 31, 2023, and its subsequent reports on Form 10-Q and current reports on Form 8-K. The foregoing sets forth many, but not all, of the factors that could cause actual results to differ from Aptevo’s expectations in any forward-looking statement. Any forward-looking statement speaks only as of the date of this press release, and, except as required by law, Aptevo does not assume any obligation to update any forward-looking statement to reflect new information, events, or circumstances.
 

CONTACT:
Miriam Weber Miller

Head, Investor Relations & Corporate Communications

Aptevo Therapeutics

Email: IR@apvo.com or Millerm@apvo.com

Phone: 206-859-6628

 


 

 

 

2

 GRAPHIC 3 img237228349_0.jpg GRAPHIC begin 644 img237228349_0.jpg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end EX-101.SCH 4 apvo-20240305.xsd XBRL TAXONOMY EXTENSION SCHEMA WITH EMBEDDED LINKBASES DOCUMENT 100000 - Document - Document And Entity Information link:presentationLink link:calculationLink link:definitionLink Cover [Abstract] Amendment Flag City Area Code Document Period End Date Document Type Entity Address, Address Line One Entity Address, Address Line Two Entity Address, City or Town Entity Address, Postal Zip Code Entity Address, State or Province Entity Central Index Key Entity Emerging Growth Company Entity File Number Entity Incorporation, State or Country Code Entity Information, Former Legal or Registered Name Entity Registrant Name Entity Tax Identification Number Local Phone Number Pre-commencement Issuer Tender Offer Pre-commencement Tender Offer Title of 12(b) Security Security Exchange Name Soliciting Material Trading Symbol Written Communications XML 5 R1.htm IDEA: XBRL DOCUMENT v3.24.0.1
Document And Entity Information
Mar. 05, 2024
Cover [Abstract]  
Document Type 8-K
Amendment Flag false
Document Period End Date Mar. 05, 2024
Entity Registrant Name APTEVO THERAPEUTICS INC.
Entity Central Index Key 0001671584
Entity Emerging Growth Company false
Entity File Number 001-37746
Entity Incorporation, State or Country Code DE
Entity Tax Identification Number 81-1567056
Entity Address, Address Line One 2401 4th Avenue
Entity Address, Address Line Two Suite 1050
Entity Address, City or Town Seattle
Entity Address, State or Province WA
Entity Address, Postal Zip Code 98121
City Area Code (206)
Local Phone Number 838-0500
Entity Information, Former Legal or Registered Name Not Applicable
Written Communications false
Soliciting Material false
Pre-commencement Tender Offer false
Pre-commencement Issuer Tender Offer false
Title of 12(b) Security Common Stock, $0.001 par value
Trading Symbol APVO
Security Exchange Name NASDAQ
EXCEL 7 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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end XML 8 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 9 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 11 FilingSummary.xml IDEA: XBRL DOCUMENT 3.24.0.1 html 1 24 1 false 0 0 false 0 false false R1.htm 100000 - Document - Document And Entity Information Sheet http://aptevotherapeutics.com/20240305/taxonomy/role/DocumentDocumentAndEntityInformation Document And Entity Information Cover 1 false false All Reports Book All Reports apvo-20240305.htm apvo-20240305.xsd http://xbrl.sec.gov/dei/2023 false false JSON 13 MetaLinks.json IDEA: XBRL DOCUMENT { "version": "2.2", "instance": { "apvo-20240305.htm": { "nsprefix": "apvo", "nsuri": "http://aptevotherapeutics.com/20240305", "dts": { "inline": { "local": [ "apvo-20240305.htm" ] }, "schema": { "local": [ "apvo-20240305.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd", "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd", "https://www.xbrl.org/dtr/type/2022-03-31/types.xsd", "https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd", "https://xbrl.fasb.org/srt/2023/elts/srt-roles-2023.xsd", "https://xbrl.fasb.org/srt/2023/elts/srt-types-2023.xsd", "https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd", "https://xbrl.fasb.org/us-gaap/2023/elts/us-roles-2023.xsd", "https://xbrl.fasb.org/us-gaap/2023/elts/us-types-2023.xsd", "https://xbrl.sec.gov/country/2023/country-2023.xsd", "https://xbrl.sec.gov/dei/2023/dei-2023.xsd" ] } }, "keyStandard": 24, "keyCustom": 0, "axisStandard": 0, "axisCustom": 0, "memberStandard": 0, "memberCustom": 0, "hidden": { "total": 2, "http://xbrl.sec.gov/dei/2023": 2 }, "contextCount": 1, "entityCount": 1, "segmentCount": 0, "elementCount": 25, "unitCount": 0, "baseTaxonomies": { "http://xbrl.sec.gov/dei/2023": 24 }, "report": { "R1": { "role": "http://aptevotherapeutics.com/20240305/taxonomy/role/DocumentDocumentAndEntityInformation", "longName": "100000 - Document - Document And Entity Information", "shortName": "Document And Entity Information", "isDefault": "true", "groupType": "document", "subGroupType": "", "menuCat": "Cover", "order": "1", "firstAnchor": { "contextRef": "C_a8198e1e-44d2-485d-9134-97cad153d00f", "name": "dei:DocumentType", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "p", "body", "html" ], "reportCount": 1, "baseRef": "apvo-20240305.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_a8198e1e-44d2-485d-9134-97cad153d00f", "name": "dei:DocumentType", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "p", "body", "html" ], "reportCount": 1, "baseRef": "apvo-20240305.htm", "first": true, "unique": true } } }, "tag": { "dei_AmendmentFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "AmendmentFlag", "presentation": [ "http://aptevotherapeutics.com/20240305/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Amendment Flag", "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission." } } }, "auth_ref": [] }, "dei_CityAreaCode": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "CityAreaCode", "presentation": [ "http://aptevotherapeutics.com/20240305/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "City Area Code", "documentation": "Area code of city" } } }, "auth_ref": [] }, "dei_CoverAbstract": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "CoverAbstract", "lang": { "en-us": { "role": { "label": "Cover [Abstract]", "documentation": "Cover page." } } }, "auth_ref": [] }, "dei_DocumentPeriodEndDate": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentPeriodEndDate", "presentation": [ "http://aptevotherapeutics.com/20240305/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Document Period End Date", "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD." } } }, "auth_ref": [] }, "dei_DocumentType": { "xbrltype": "submissionTypeItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentType", "presentation": [ "http://aptevotherapeutics.com/20240305/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Document Type", "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'." } } }, "auth_ref": [] }, "dei_EntityAddressAddressLine1": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressAddressLine1", "presentation": [ "http://aptevotherapeutics.com/20240305/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Address, Address Line One", "documentation": "Address Line 1 such as Attn, Building Name, Street Name" } } }, "auth_ref": [] }, "dei_EntityAddressAddressLine2": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressAddressLine2", "presentation": [ "http://aptevotherapeutics.com/20240305/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Address, Address Line Two", "documentation": "Address Line 2 such as Street or Suite number" } } }, "auth_ref": [] }, "dei_EntityAddressCityOrTown": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressCityOrTown", "presentation": [ "http://aptevotherapeutics.com/20240305/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Address, City or Town", "documentation": "Name of the City or Town" } } }, "auth_ref": [] }, "dei_EntityAddressPostalZipCode": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressPostalZipCode", "presentation": [ "http://aptevotherapeutics.com/20240305/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Address, Postal Zip Code", "documentation": "Code for the postal or zip code" } } }, "auth_ref": [] }, "dei_EntityAddressStateOrProvince": { "xbrltype": "stateOrProvinceItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressStateOrProvince", "presentation": [ "http://aptevotherapeutics.com/20240305/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Address, State or Province", "documentation": "Name of the state or province." } } }, "auth_ref": [] }, "dei_EntityCentralIndexKey": { "xbrltype": "centralIndexKeyItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityCentralIndexKey", "presentation": [ "http://aptevotherapeutics.com/20240305/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Central Index Key", "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK." } } }, "auth_ref": [ "r1" ] }, "dei_EntityEmergingGrowthCompany": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityEmergingGrowthCompany", "presentation": [ "http://aptevotherapeutics.com/20240305/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Emerging Growth Company", "documentation": "Indicate if registrant meets the emerging growth company criteria." } } }, "auth_ref": [ "r1" ] }, "dei_EntityFileNumber": { "xbrltype": "fileNumberItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityFileNumber", "presentation": [ "http://aptevotherapeutics.com/20240305/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity File Number", "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen." } } }, "auth_ref": [] }, "dei_EntityIncorporationStateCountryCode": { "xbrltype": "edgarStateCountryItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityIncorporationStateCountryCode", "presentation": [ "http://aptevotherapeutics.com/20240305/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Incorporation, State or Country Code", "documentation": "Two-character EDGAR code representing the state or country of incorporation." } } }, "auth_ref": [] }, "dei_EntityInformationFormerLegalOrRegisteredName": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityInformationFormerLegalOrRegisteredName", "presentation": [ "http://aptevotherapeutics.com/20240305/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Information, Former Legal or Registered Name", "documentation": "Former Legal or Registered Name of an entity" } } }, "auth_ref": [] }, "dei_EntityRegistrantName": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityRegistrantName", "presentation": [ "http://aptevotherapeutics.com/20240305/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Registrant Name", "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC." } } }, "auth_ref": [ "r1" ] }, "dei_EntityTaxIdentificationNumber": { "xbrltype": "employerIdItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityTaxIdentificationNumber", "presentation": [ "http://aptevotherapeutics.com/20240305/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Tax Identification Number", "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS." } } }, "auth_ref": [ "r1" ] }, "dei_LocalPhoneNumber": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "LocalPhoneNumber", "presentation": [ "http://aptevotherapeutics.com/20240305/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Local Phone Number", "documentation": "Local phone number for entity." } } }, "auth_ref": [] }, "dei_PreCommencementIssuerTenderOffer": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "PreCommencementIssuerTenderOffer", "presentation": [ "http://aptevotherapeutics.com/20240305/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Pre-commencement Issuer Tender Offer", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act." } } }, "auth_ref": [ "r3" ] }, "dei_PreCommencementTenderOffer": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "PreCommencementTenderOffer", "presentation": [ "http://aptevotherapeutics.com/20240305/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Pre-commencement Tender Offer", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act." } } }, "auth_ref": [ "r4" ] }, "dei_Security12bTitle": { "xbrltype": "securityTitleItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "Security12bTitle", "presentation": [ "http://aptevotherapeutics.com/20240305/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Title of 12(b) Security", "documentation": "Title of a 12(b) registered security." } } }, "auth_ref": [ "r0" ] }, "dei_SecurityExchangeName": { "xbrltype": "edgarExchangeCodeItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "SecurityExchangeName", "presentation": [ "http://aptevotherapeutics.com/20240305/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Security Exchange Name", "documentation": "Name of the Exchange on which a security is registered." } } }, "auth_ref": [ "r2" ] }, "dei_SolicitingMaterial": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "SolicitingMaterial", "presentation": [ "http://aptevotherapeutics.com/20240305/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Soliciting Material", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act." } } }, "auth_ref": [ "r5" ] }, "dei_TradingSymbol": { "xbrltype": "tradingSymbolItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "TradingSymbol", "presentation": [ "http://aptevotherapeutics.com/20240305/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Trading Symbol", "documentation": "Trading symbol of an instrument as listed on an exchange." } } }, "auth_ref": [] }, "dei_WrittenCommunications": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "WrittenCommunications", "presentation": [ "http://aptevotherapeutics.com/20240305/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Written Communications", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act." } } }, "auth_ref": [ "r6" ] } } } }, "std_ref": { "r0": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b" }, "r1": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b-2" }, "r2": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "d1-1" }, "r3": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "13e", "Subsection": "4c" }, "r4": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "14d", "Subsection": "2b" }, "r5": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Section": "14a", "Number": "240", "Subsection": "12" }, "r6": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Securities Act", "Number": "230", "Section": "425" } } } ZIP 14 0000950170-24-025427-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0000950170-24-025427-xbrl.zip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�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end XML 15 apvo-20240305_htm.xml IDEA: XBRL DOCUMENT 0001671584 2024-03-05 2024-03-05 0001671584 false 8-K 2024-03-05 APTEVO THERAPEUTICS INC. DE 001-37746 81-1567056 2401 4th Avenue Suite 1050 Seattle WA 98121 (206) 838-0500 Not Applicable false false false false Common Stock, $0.001 par value APVO NASDAQ false